Search the web
Welcome, Guest
[Sign Out, My Account]
Hoovers

Sunday, December 21 2014 9:11pm ET - U.S. Markets Closed.
Industry Center - Biotechnology
Industry Center > Biotechnology > Gilead Sciences, Inc. Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
  
Gilead Sciences, Inc. Company Profile
Gilead Sciences has biotech balms for infectious diseases, including hepatitis, HIV, and infections related to AIDS. The company's HIV franchise includes Truvada, a combination of two of its other drugs, Viread and Emtriva. It co-promotes another HIV treatment, called Atripla, in the US and Europe with Bristol-Myers Squibb (BMS). Other products on the market include AmBisome, used to treat systemic fungal infections such as those that accompany AIDS or kidney disease; Vistide, for AIDS-related eye infections; and hepatitis B antiviral Hepsera. Beyond HIV/AIDS, Gilead also markets cardiovascular drugs Letairis and Ranexa, as well as respiratory and ophthalmic medicines.
Headlines for Gilead Sciences, Inc.
6:02 am Gilead Sciences and Ono Pharma (<a href="/q?s=ophly" name="ophly">OPHLY</a>) announced that the companies have entered into an exclusive license agreement for the development and commercialization of ONO-4059
- Sun 6:02 am ET
U.S. FDA approves AbbVie hepatitis C drug, costs $83,319 for 12 weeks
Reuters - Fri Dec 19
AbbVie's Hepatitis-C Treatment Approved, Bad news for Gilead?
at Barrons.com - Fri Dec 19
United Therapeutics Lung Drug Keeps Going And Going
at Investor's Business Daily, Inc. - Fri Dec 19
More Headlines...
More on Gilead Sciences, Inc.
Quote Msgs
Chart Insider
News Financials
Profile Analyst Ratings
Research    
SEC    
Contact Information
Address: 333 Lakeside Dr.
Foster City, CA 94404
Phone:650-574-3000
Fax:650-578-9264
Financial Highlights
Fiscal Year End:December
Revenue (2013):11201.70 M
Revenue Growth (1 yr):15.50%
Employees (2013):6,100
Employee Growth (1 yr):22.00%
Key People
Chairman and CEO: John C. Martin
President and COO: John F. Milligan
EVP and CFO: Robin L. Washington
Industry Information
Sector: Healthcare
Industry: Biotechnology
Top Competitors
GlaxoSmithKline plc (gsk)
Pfizer Inc. (pfe)
Roche Holding Ltd (rhhby)
 


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2014 Morningstar, Inc. All Rights Reserved. Company information © 2014 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2014, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?